PGI set to give second dose of Oxford vaccine tomorrow

Phase 2/3 trials: 100 volunteers were administered first dose of Oxford-AstraZeneca vaccine, Covishield

PGI set to give second dose of Oxford vaccine tomorrow

Naina Mishra

Tribune News Service

Chandigarh, October 21

The Post Graduate Institute of Medical Education and Research (PGI) today completed the first dose of vaccination of 100 volunteers for the late-phase human clinical trials of the Oxford-AstraZeneca vaccine, also known as Covishield in India.

The second dose is to be given after 28 days of the first dose, which will be on October 23. The institute has so far screened 143 candidates for the vaccine.

 Dr Jagat Ram, PGI Director

‘All volunteers safe’

It is a big achievement. All volunteers are safe without much side effects. This vaccine will be beneficial for the masses to prevent the Covid-19 infection.

One among the vaccine volunteers is a 64-year-old senior doctor of the PGI. He said, “I have comorbidities such as hypertension and diabetes. I considered exposing myself to find out what effect the vaccine will have on elderly people with comorbidities like me. This is for the cause of mankind and I am willing to risk it even at the cost of my well-being.”

He said, “So far, I am doing well and have completed 23 days ever since the first dose. Initially, I developed fever and mild aches in the body, but recovered quickly. I feel fine ever since then.”

As per the protocol, Covishield or Placebo or Oxford/AZ-ChAdOx1 will be administered under a two-dose schedule on day one and 29 as 0.5 ml dose intramuscularly.

64-year-old PGI doc

‘For the cause of mankind’

I have hypertension and diabetes. I considered exposing myself to find out what effect the vaccine will have on elderly people with comorbidities like me. This is for the cause of mankind and I am willing to risk it even at the cost of my well-being.

This is a phase two/three, observer-blind, randomised, controlled study in healthy adults in India for comparison of the safety of Covishield with Oxford/AZ-ChAdOx1 nCoV-19 and Placebo, and immunogenicity with Oxford/AZ-ChAdOx1 nCoV-19 in the prevention of the SARS CoV-2 infection.

Both Covishield and the Oxford/ChAdOx1 have the same virus protein but differ in their make — the exact nature of the difference has not been publicly disclosed. The trial also seeks to quantify these differences, if any.

The trial involves 1,600 volunteers in 17 cities across the country likely to be inoculated in the coming months in the combined phase two/three trials. These trials check whether the vaccine is safe and capable of producing an immune response to disarm future infections by the SARS-CoV-2 virus.

Top Stories

Union ministers meet farmers’ groups to break deadlock

Union ministers meet farmers’ groups to break deadlock

The government said that the meeting started in the afternoo...

Appeal to farmers to resolve crisis, agitation impacting national security, Punjab economy: Amarinder

Appeal to farmers to resolve crisis, agitation impacting national security, Punjab economy: Amarinder

Capt Amarinder may also be part of the deliberations the Cen...

As Shah meets Amarinder, govt contemplating new offer to farmers?

As Shah meets Amarinder, govt contemplating new offer to farmers?

It may include holding back the three Acts for a couple of m...

Prakash Singh Badal returns Padma Vibhushan in protest against farm laws

Prakash Singh Badal returns Padma Vibhushan in protest against farm laws

"The most painful and embarrassing moment in my long politic...

Cities

View All